A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

Renowned Hindi and Marathi actress Pravina Deshpande passed away at 60 after battling multiple myeloma since 2019. Known for Ghar Ek Mandir, Kumkum, and films like Ready, she faced skin eruptions, ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

The management of treatment side effects can expand caregiver duties significantly, and can involve working more closely with the healthcare team. The symptoms related to multiple myeloma, such as ...

Experts discuss the importance of transitioning cancer care from academic centers to community practices, ensuring patient ...

Your doctor tells you your multiple myeloma is in remission. But what exactly does that mean? The first thing to understand is that being in remission is not the same thing as being cured. The ...

Every year, scientists learn more about multiple myeloma, a type of blood cancer that starts in your bones. They’re working to figure out what causes this cancer and why some groups have a higher ...